New Collaboration Seeks Improved Breast Cancer Diagnostics
Breast cancer is the uncontrollable growth of tumour cells in the breasts. Generally, the cancer forms in either the lobules or the ducts of the breast. There are two types of breast cancers, invasive breast cancer and non-invasive breast cancer. During recent years, there has been an increase in the cases of breast cancer in women. Recently, breast cancer is also being detected in men. The American Cancer Society estimated that in 2015, more than 2,000 men would be diagnosed, and more than 400 men would die from the disease.
Breast cancer has become the most common type of cancer for women across the globe. The number of women suffering from breast cancer is witnessing a surge. This has led towards necessity for efficient early detection of breast cancer. Mammography screening, an established method adopted across several countries, has been recently been observed to offer inconclusive test results. Risk-adapted, personalized therapy and screening are predicted to resolve these difficulties. In addition, tomosynthesis, a new imaging technology, has been seen to overcome the drawbacks of mammography.
Download PDF Brochure Here
Screening options for breast cancer have been witnessing a rise, and have been altering practices of early detection across industrialized economies. Moreover, countries such as Brazil, India and China are focusing on development of cost-effective screening strategies capable of being adapted as per requirements.
The study will take advantage of Thermo Fisher’s Oncomine Comprehensive Assay, a targeted, next-generation sequencing (NGS) research tool that analyzes 143 genes relevant to cancer. The data generated can be further studied with the Oncomine Knowledgebase Reporter—a curated set of published evidence that matches driver genetic variants with relevant information, such as on-market drugs, available clinical trials, or published studies. The findings of the OICR study will be used to assess the technology and could inform subsequent clinical trials.
The Ontario Institute for Cancer Research (OICR) announced today that it is teaming up with Queen’s University and Thermo Fisher Scientific to help bring more targeted diagnosis and treatment to breast cancer patients. The new collaboration aims to identify mutations and copy number changes found in breast cancer samples and establish whether these abnormalities correlate with on-market drugs, available clinical trials, or published studies.
Key market players mentioned in Fact.MR’s report include Abbott Laboratories, Roche Holding AG, Thermo Fischer Scientific, Inc., Siemens AG, Bio-Rad Laboratories, Inc., Illumina, Inc., Biocept, Inc., Epigenomics AG, AstraZeneca plc, Myriad Genetics, Inc., and Quest Diagnostics Incorporated.
Source: clinicalomics & The Insight Partners